Skip to content
Search AI Powered

Latest Stories

Wockhardt UK stops production of Diazepam RecTubes®2.5mg due to “manufacturing issues”

Wockhardt UK, one of the largest generic pharmaceutical companies in the UK, has discontinued production of Diazepam RecTubes® 2.5mg Rectal Solution “due to manufacturing issues”.

The available stocks of the medicine are expected to be exhausted by March 2022, the Department of Health and Social Care (DH) and NHS England and Improvement (NHSE&I) stated in a supply disruption alert.


The medication is licensed for use in patients aged one year and above for treating epileptic and febrile convulsions, acute severe anxiety and agitation, tetanus.

It is also used as a sedative in minor surgical and dental procedures.

DHSC has advised all healthcare professionals to not initiate new patients on Diazepam RecTubes® 2.5mg, and update patient’s epilepsy passport/ child’s emergency care plans if any changes to treatment are needed.

They should also review all patient prescriptions having Diazepam RecTubes 2.5mg and consider alternatives where appropriate.

“Diazepam 5mg/ 2.5mL rectal solution remains available and can support an uplift in demand,” DHSC said.

Besides parents and careres should be counselled appropriately on the new treatment regimen including when to access emergency assistance where required.

More For You

New professional liability insurance policy for RPS members launched

The insurance will be provided to members at cost, with no profit made by RPS.

gettyimages

RPS launches professional liability insurance for members

The Royal Pharmaceutical Society (RPS) has launched a new professional liability insurance policy, designed to empower pharmacists to work confidently and deliver high-quality care, knowing they are protected.

Exclusively available to its members, the comprehensive and affordable insurance has been developed in collaboration with global professional services firm Aon.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less